Compare Abrdn Physical Platinum Shares ETF (PPLT) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abrdn Physical Platinum Shares ETF vs Revvity Inc — how do they compare? Abrdn Physical Platinum Shares ETF trades at $16.88, while Revvity Inc trades at $124.14 (market cap $13.82B). The key difference: Revvity Inc pays a 0.23% dividend while Abrdn Physical Platinum Shares ETF pays none, and Revvity Inc is trading nearer its 52-week high, Abrdn Physical Platinum Shares ETF nearer its low. Which is the better fit depends on your goals.
| PPLT | RVTY | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Technology |
52-Week High | $25.23 | $130.94 |
52-Week Low | $12.38 | $82.26 |
Market Cap | — | $13.82B |
Enterprise Value | — | $16.14B |
Dividend Yield | — | 0.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PPLT (abrdn Platinum ETF Trust) trades at $16.46, down 0.24% with a bullish technical signal from moving averages. The ETF tracks physical platinum prices, which have lagged behind gold and silver's recent rally. Recent news highlights platinum's potential catch-up trade opportunity as price ratios suggest potential mean reversion. Technical indicators show mixed signals with neutral oscillators but strong trend strength from ADX.
The outlook suggests potential upside as platinum seeks to close its performance gap with other precious metals. Key risks include commodity price volatility and macroeconomic factors affecting industrial demand. Investment opportunity lies in platinum's historical tendency for mean reversion and its dual role as both precious metal and industrial commodity.
RVTY trades at $127.08, down 2.41% on the day, with a bullish technical signal from moving averages and strong support at $126. The company reported Q2 2026 EPS of $1.41, beating estimates, and raised its full-year outlook, driven by diagnostics strength and improved cash flow. Recent news includes the acquisition of Human Cell Design and the launch of the SuperFlex prenatal screening system.
Outlook is positive with 52% analyst buy ratings and a $135.25 consensus price target, implying ~6% upside. Risks include a premium valuation (P/E 61.1) and execution of growth initiatives. Strong institutional interest, such as Bank of New York Mellon's $78.77 million investment, supports confidence in the stock's trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abrdn Physical Platinum Shares ETF
PPLT is a physically-backed ETF designed to track the spot price of platinum, less the Trust's expenses. It holds physical platinum bullion in secure vaults, providing investors with a liquid and cost-effective way to access the platinum market without the logistical challenges of direct ownership.
Read more on PPLT →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
